Biomarin Pharmaceutical (BMRN) Long-Term Investments (2009 - 2025)

Biomarin Pharmaceutical (BMRN) has 17 years of Long-Term Investments data on file, last reported at $492.2 million in Q4 2025.

• Quarterly Long-Term Investments fell 5.56% year-over-year to $492.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $492.2 million (down 5.56% YoY) and the FY2025 annual result came in at $492.2 million, down 5.56% from the prior year.
• Long-Term Investments eased to $492.2 million in Q4 2025, from $512.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $620.6 million in Q1 2024 to a low of $321.1 million in Q1 2021.
• A 5-year average of $469.7 million and a median of $499.5 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments tumbled 34.26% — and 2023, when it jumped 83.06%.
• Tracing BMRN's Long-Term Investments over 5 years: stood at $507.8 million in 2021, then plunged by 34.26% to $333.8 million in 2022, then jumped by 83.06% to $611.1 million in 2023, then dropped by 14.71% to $521.2 million in 2024, then slipped by 5.56% to $492.2 million in 2025.
• The last three Long-Term Investments figures came in at $492.2 million (Q4 2025), $512.9 million (Q3 2025), and $508.6 million (Q2 2025), per Business Quant data.